1. Clinical Overview
A sterile, topical ophthalmic suspension combining a fourth-generation fluoroquinolone antibiotic (Gatifloxacin) with a potent corticosteroid (Prednisolone acetate). It is designed for the treatment of steroid-responsive inflammatory ocular conditions where the risk of superficial bacterial infection is high or where there is an existing bacterial infection. The combination provides broad-spectrum antibacterial coverage and potent anti-inflammatory action.
| Onset | Duration | Bioavailability |
|---|---|---|
| Anti-inflammatory effects of prednisolone may be observed within hours. Antibacterial effects of gatifloxacin begin rapidly upon contact with susceptible organisms. | Local duration is approximately 4-6 hours per instillation, necessitating multiple daily doses. Systemic effects are minimal due to topical administration. | Negligible systemic bioavailability following topical ocular administration (<1%). Primarily acts locally. |
2. Mechanism of Action
Gatifloxacin inhibits bacterial DNA gyrase (Topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to rapid bacterial cell death. Prednisolone acetate is a glucocorticoid that binds to cytoplasmic receptors, translocates to the nucleus, and modulates gene transcription. It inhibits the release of inflammatory mediators (prostaglandins, leukotrienes), reduces capillary permeability, leukocyte migration, and fibroblast proliferation, thereby suppressing inflammation.
3. Indications & Uses
- Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the risk of bacterial ocular infection is high.
- Post-operative ocular inflammation following cataract surgery or other intraocular procedures.
- Ocular conditions where both anti-inflammatory and anti-bacterial effects are required (e.g., severe blepharoconjunctivitis, keratoconjunctivitis).
4. Dosage & Administration
Adult Dosage: One drop instilled into the affected eye(s) every 4 to 6 hours. In severe inflammation, one drop every 1-2 hours initially, tapering frequency as inflammation subsides. Duration typically not to exceed 10-14 days without re-evaluation.
Administration: 1. Wash hands. 2. Shake the suspension well before use. 3. Tilt head back, pull lower eyelid down to form a pouch. 4. Instill prescribed drops without touching the tip to eye or any surface. 5. Close eyes gently and apply pressure at the inner corner of the eye (nasolacrimal occlusion) for 1-2 minutes to minimize systemic absorption. 6. Wait at least 5-10 minutes before instilling any other eye drops.
5. Side Effects
Common side effects may include:
- Transient ocular burning/stinging upon instillation
- Blurred vision temporarily after instillation
- Foreign body sensation
- Mild conjunctival hyperemia
- Taste perversion (bitter taste) due to nasolacrimal drainage
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Corticosteroids (oral, topical, inhaled) | Additive risk of systemic corticosteroid side effects (hyperglycemia, adrenal suppression). | Moderate |
| Non-steroidal Anti-inflammatory Drugs (NSAIDs) topical (e.g., Ketorolac, Nepafenac) | Increased risk of corneal adverse events (ulceration, perforation) especially post-surgery. | Major |
| Cholinesterase Inhibitors (e.g., Echothiophate iodide) used in glaucoma | Concurrent use may reduce the activity of cholinesterase inhibitors. | Moderate |
| Anticoagulants (e.g., Warfarin) | Theoretical risk of altered INR due to systemic absorption of steroid; monitor INR. | Minor |
7. Patient Counselling
- DO shake the bottle well before each use.
- DO use exactly as prescribed, at evenly spaced intervals.
- DO apply nasolacrimal occlusion (pressing inner corner of eye) for 1-2 minutes after instillation.
- DO wait at least 5-10 minutes before using other eye medications.
- DO NOT touch the dropper tip to any surface (eye, fingers) to avoid contamination.
- DO NOT wear contact lenses during treatment unless specifically advised by doctor.
- DO NOT stop medication abruptly if used for more than 10 days; taper as directed.
- DO NOT share your eye drops with anyone.
8. Toxicology & Storage
Overdose: Topical overdose is unlikely to cause systemic toxicity. Symptoms may include severe ocular irritation, pain, redness, and worsening of side effects. Accidental oral ingestion of bottle contents may lead to systemic quinolone and steroid effects: nausea, vomiting, dizziness, hyperglycemia.
Storage: Store at controlled room temperature (15°C to 25°C). Protect from light. Do not freeze. Keep the bottle tightly closed when not in use. Discard the bottle 4 weeks after opening to prevent contamination. Keep out of reach of children.